Lombard, IL, United States of America

Sarki A Abdulkadir

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
5 patents (USPTO):

Title: Innovations of Sarki A Abdulkadir

Introduction

Sarki A Abdulkadir is a notable inventor based in Lombard, IL (US). He has made significant contributions to the field of therapeutics, particularly in the development of compounds that target cancer-related proteins. With a total of five patents to his name, Abdulkadir's work is paving the way for innovative treatments in oncology.

Latest Patents

Among his latest patents, Abdulkadir has developed substituted heterocycles as c-MYC targeting agents. These compounds, which include substituted pyrazoles, substituted pyrimidines, and substituted triazoles, are designed to inhibit c-MYC, a protein implicated in cancer and cell proliferative disorders. Another significant patent involves proteolysis-targeting chimeric molecules (PROTACs) that induce the degradation of c-MYC protein. These PROTACs consist of a targeting moiety that binds to c-MYC and is linked to another moiety that binds to an E3 ubiquitin ligase, showcasing a novel approach to cancer treatment.

Career Highlights

Sarki A Abdulkadir is affiliated with Northwestern University, where he continues to advance his research and innovation in the field of cancer therapeutics. His work is characterized by a strong focus on developing targeted therapies that can effectively combat cancer at the molecular level.

Collaborations

Abdulkadir collaborates with esteemed colleagues such as Gary E Schiltz and Huiying Han, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Sarki A Abdulkadir's contributions to the field of cancer therapeutics through his innovative patents highlight his role as a leading inventor. His work not only advances scientific knowledge but also holds the potential to improve treatment options for patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…